In February, CIM travelled to Madrid, Spain to take part in the 2020 Advanced Technologies & Treatments for Diabetes (ATTD) conference. We took in as much as we could and shared through both Instagram and Twitter in real time, but, of course, there was way more that we wanted to pass on. Today, we’re taking the time to share key learnings from Omnipod’s presentations at the conference. You can also read about updates from Dexcom, Abbott, and Medtronic.
Disclaimer: Please check out CIM’s Partners Page to learn more about the companies we work with. This post was not paid for and does not represent sponsored content, but it’s important to recognize that we may be biased based on the fact that some companies highlighted below support CIM in different ways. We still thought this info was important for you to know about.
Summary:
- The Omnipod DASH system (soon to be launched in Canada)
- Insulin-Abbott partnership
- Insulet-Dexcom partnership
We are excitedly waiting for the Omnipod Dash system to come to Canada. The system received its FDA clearance in June 2018 and has been available south of the border for some time. We got to see the product in action at ATTD. The Omnipod Dash system paves the way for future innovation and, although there are only a few major updates, the updates that exist give a glimpse into what will be possible with the Omnipod system in coming years and can leave us daydreaming about what is in the pipeline. The Omnipod Dash system features a new blue-tooth enabled PDM device that is built on a cell phone platform. The PDM does not operate as a cellular phone, but paves the way for future cell phone enabled innovation, including what we’ll see soon in the US with the Omnipod Horizon system, with Canada (we’re sure!) to follow closely along.
We always love a good announcement and weren’t disappointed when BOTH an Insulet-Abbott AND an Insulin-Dexcom partnership surfaced at ATTD 2020. This is especially exciting as it paves the way to more choice for people with Type 1 diabetes and begins to put into action the talk about interoperability.
The Insulet-Abbott partnership will bring together the Omnipod’s next generation Horizon system with Abbott’s FreeStyle Libre 2. Some interesting elements that this partnership will bring to the market include a system that is fully purchasable at the pharmacy, as well as both the sensor and pod being fully disposable, with no non-disposable pieces as part of the puzzle (like infusion sets or transmitters.) The partnership also demonstrates a movement towards more interoperable devices, helping provide more choice for people with Type 1 diabetes.
The Insulet-Dexcom partnership will allow the integration of not only the Dexcom G6 but also the forthcoming Dexcom G7. There is currently a pivotal trial underway assessing this new integrated system. The Omnipod Horizon system will allow control of Pods via a smartphone app and will use Dexcom’s continuous glucose monitoring technology to adjust insulin dosing based on readings from the CGM.
To learn more about what Omnipod has on the go and to stay updated, visit their websites:
Canada: https://www.myomnipod.com/en-ca/home
USA: https://www.myomnipod.com/home
